Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Study sheds new light on genetic risk factors that make individuals susceptible to severe COVID-19

Even as tens of thousands of Americans test positive for COVID-19 each day, physicians still aren't sure why some people experience mild to no symptoms while others become critically ill.

25 Nov 2020

Inhibiting SARS-CoV-2 cell entry with monoclonal antibodies against staphylococcal enterotoxin B superantigen

In a recent cutting-edge study, US researchers unveiled an anti-staphylococcal enterotoxin B monoclonal antibody that can be repurposed to target the cleavage site of the SARS-CoV-2 spike glycoprotein and, in turn, inhibit viral infection. Their findings are currently available on bioRxiv preprint server.

25 Nov 2020

New drug treatment could soon benefit people with rheumatoid arthritis

People with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment that not only suppresses inflammation but also significantly reduces patient reported pain scores. Otilimab is a monoclonal antibody, biologic drug, which targets and suppresses the inflammatory cytokine GM-CSF.

25 Nov 2020

SARS-CoV-2 spike protein antibodies can persist up to 200 days after symptom onset

Researchers report SARS-CoV-2 antibodies to the spike protein (S protein) can persist 200 days after symptom onset, but that antibodies to the nucleoprotein (N protein) can reduce much more rapidly.

25 Nov 2020

Is COVID-19 severity mediated by higher antibody response?

A new study indicates that patients with more severe COVID-19 have a stronger antibody response.

25 Nov 2020

Robust antibody response to SARS-CoV-2 can persist for eight months, study finds

A study conducted by researchers based in Italy suggests that SARS-CoV-2 induces durable and strong immunity in patients who had moderate to severe COVID-19.

25 Nov 2020

Protection of upper respiratory tract will require vaccines that mimic natural infection by SARS-CoV-2

Recently, a team of researchers studied the transmission modes of SARS-CoV-2 and the protection against re-infection in ferret models in work published on the preprint server, bioRxiv.

24 Nov 2020

Mild COVID-19 disease may trigger long-term immunity

Researchers in the United States have conducted a study showing that individuals who have recovered from mild coronavirus disease 2019 (COVID-19) developed sustained protective immune memory against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

24 Nov 2020

Sex steroids may play a protective role in COVID-19, shows study

A new paper from a UIC researcher shows evidence that suggests sex steroids may play a role in protecting against COVID-19 symptoms.

24 Nov 2020

Scientists show SARS-CoV-2's viral replication with 3D integrative imaging

A team of researchers at Heidelberg University in Germany have performed a detailed imaging analysis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to determine how the virus reprograms infected cells.

24 Nov 2020

Researchers recommend antibody cocktail to tackle SARS-CoV-2 mutations

A new study released on the medRxiv* preprint server indicates that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic – is developing multiple mutations that affect neutralization by antibodies.

24 Nov 2020

Biosensor assay SARS-CoV-2 antibody test may predict COVID-19 severity in patients

Researchers in New York, USA, have found an association of mortality with an early humoral response to SARS-CoV-2 infection within the first few days after onset of symptoms (DAOS), using a highly sensitive and automated testing-on-a-probe (TOP) biosensor assays for SARS-CoV-2.

24 Nov 2020

FairJourney Biologics and IONTAS sign agreement with Pandion Therapeutics to discover antibodies

FairJourney Biologics S.A (FJB) and IONTAS Limited, leaders in the discovery and optimization of VHH and fully human antibodies, today announced they have signed an agreement to discover antibodies with Pandion Therapeutics.

24 Nov 2020

First checkpoint inhibitor vaccine shown to be safe, effective in colon cancer animal model

A study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute described a potential therapeutic anticancer vaccine that frees suppressed cancer-killing immune cells, enabling them to attack and destroy a tumor.

23 Nov 2020

SARS-CoV-2 spike deletion mutations may evade current vaccine candidates, study finds

A thought-provoking new study reports that the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antibodies elicited by natural infection may not be able to neutralize emerging strains that display deletion mutations in their genomic RNA.

23 Nov 2020

Modified SARS-CoV-2 receptor-binding domain could increase vaccine efficacy, says study

A team of researchers from the USA and China have engineered a receptor-binding domain (RBD) that they claim improves the immunogenicity of multivalent SARS-CoV-2 vaccines. Their study, which was released on the bioRxiv* in November 2020, may help advance even more efficacious SARS-CoV-2 vaccine candidates in the future.

23 Nov 2020

Researchers develop recombinant SARS-CoV-2 model to aid vaccine and antiviral research

Researchers have developed a fluorescent reporter gene-bearing recombinant form of SARS-CoV-2, which is capable of replication.

23 Nov 2020

Chicago seroprevalence study shows COVID-19 cases 16 times higher than currently predicted

A startling new case study of Chicago, led by a team of researchers at Northwestern University in Illinois, USA, suggests a 16-fold higher incidence of SARS-CoV-2 infection than previously thought. This is judging from seroprevalence (antibody presence blood testing) figures, rather than the number of RT-PCR-positives reported there (via swab sample testing of symptomatic patients).

23 Nov 2020

FDA schedules meeting to discuss emergency use authorization of COVID-19 vaccine from Pfizer

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19.

23 Nov 2020

SARS-Cov-2 antibodies are detected up to 3 months after infection, shows study

A new study in health care workers led by the Barcelona Institute for Global Health (ISGlobal), an institution supported by "la Caixa" Foundation and the Hospital Clínic of Barcelona, shows that IgA and IgM antibodies to SARS-CoV-2 decay quickly, while IgG antibody levels are maintained for at least three months after infection.

23 Nov 2020

Antibody News and Research

Further Reading

Study sheds new light on genetic risk factors that make individuals susceptible to severe COVID-19

Inhibiting SARS-CoV-2 cell entry with monoclonal antibodies against staphylococcal enterotoxin B superantigen

New drug treatment could soon benefit people with rheumatoid arthritis

SARS-CoV-2 spike protein antibodies can persist up to 200 days after symptom onset

Is COVID-19 severity mediated by higher antibody response?

Robust antibody response to SARS-CoV-2 can persist for eight months, study finds

Protection of upper respiratory tract will require vaccines that mimic natural infection by SARS-CoV-2

Mild COVID-19 disease may trigger long-term immunity

Sex steroids may play a protective role in COVID-19, shows study

Scientists show SARS-CoV-2's viral replication with 3D integrative imaging

Researchers recommend antibody cocktail to tackle SARS-CoV-2 mutations

Biosensor assay SARS-CoV-2 antibody test may predict COVID-19 severity in patients

FairJourney Biologics and IONTAS sign agreement with Pandion Therapeutics to discover antibodies

First checkpoint inhibitor vaccine shown to be safe, effective in colon cancer animal model

SARS-CoV-2 spike deletion mutations may evade current vaccine candidates, study finds

Modified SARS-CoV-2 receptor-binding domain could increase vaccine efficacy, says study

Researchers develop recombinant SARS-CoV-2 model to aid vaccine and antiviral research

Chicago seroprevalence study shows COVID-19 cases 16 times higher than currently predicted

FDA schedules meeting to discuss emergency use authorization of COVID-19 vaccine from Pfizer

SARS-Cov-2 antibodies are detected up to 3 months after infection, shows study

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo